Loading...
NPI 1588776264 · East Syracuse, NY · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Tarek Sousou is a hematology & oncology physician provider located in East Syracuse, New York. This profile covers 108 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Tarek Sousou |
| Address | 5008 Brittonfield Pkwy |
| City | East Syracuse |
| State | NY |
| ZIP | 13057 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | August 31, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.2M |
| Medicaid | $700 |
Provider is effectively Medicare-focused: lifetime Medicare revenue is $4.2M compared with only $705 in Medicaid revenue, so Medicare accounts for the overwhelming majority of billed dollars and the provider operates with a near single‑payer revenue profile. This gap indicates that Medicaid revenue is immaterial to the overall business picture and that analyses of scale and competition should concentrate on Medicare activity.
Medicare revenue is highly concentrated in a small set of oncology infusions: the precomputed top 3 Medicare codes account for 53.2% of Medicare revenue, driven by J9271 ($885.8K revenue, 22.1% of Medicare revenue), J9144 ($629.3K revenue, 15.7% of Medicare revenue), and J9299 ($616.7K revenue, 15.4% of Medicare revenue). These three monoclonal antibody/immunotherapy agents dominate the provider’s Medicare billing, implying revenue exposure tied to high-cost oncology drugs.
The code mix is consistent with a hematology/oncology infusion practice: high-volume drug codes such as J9271 (pembrolizumab), J9144 (daratumumab), J9299 (nivolumab), plus infusion/administration activity (G0498 and chemotherapy administration code 96413) point to an operation centered on clinic-based IV biologic and chemotherapy delivery rather than primarily office-based evaluation and management. Presence of supportive-care agents and growth factors (e.g., J2506, J0881, J1439) further supports an infusion-centric service line with ancillary supportive therapies.
Competitive standing across top Medicare drugs is mixed but generally within typical national ranges: J9271 ranks #365 of 1841 providers nationally (80th percentile), J9144 ranks #72 of 615 (88th percentile), and J9299 ranks #100 of 505 (80th percentile), which indicates meaningful but not dominant national volumes for these immunotherapies. In short, the provider is a recognizable participant in high-cost oncology drug administration but not a national outlier or market leader for these agents.
There are a few Medicare codes flagged as above-typical volume that suggest particularly heavy chemotherapy/administration throughput relative to peers: 96413 is reported as $75.6K revenue and is described as "notably above typical national volume" (97th percentile), and J0185 is reported as $23.8K revenue and also described as "notably above typical national volume" (95th percentile). Those elevated signals imply higher-than-typical utilization of chemotherapy administration and antiemetic/supportive drug billing compared with national peers.
Medicaid billing is almost exclusively office visits and very small in scale: top Medicaid codes are 99214 (37 claims, $518 revenue, 74.2% of Medicaid revenue) and 99213 (12 claims, $180 revenue, 25.8% of Medicaid revenue), and the precomputed top-3 Medicaid share is 100.0%. This pattern shows Medicaid activity is limited to low-revenue E&M encounters and does not include the infusion/drug revenue that dominates the provider’s Medicare book.
The provider has an established billing history: NPI enumerated on 2006-08-31 (~20 years ago), indicating long tenure in the market. Combined with the concentrated $4.2M Medicare revenue base, this tenure supports the interpretation of a stable, long-running oncology practice focused on infusion services.
There is mixed utilization of biosimilars and select low-volume codes: Q5122 (pegfilgrastim-apgf) appears at $18K revenue but ranks #220 of 239 providers nationally (6th percentile), and other biosimilars such as Q5111 and Q5119 sit in lower-to-mid percentiles, suggesting limited uptake of some biosimilars relative to peers. At the same time, a few drugs (e.g., J1439, J0881) appear at high claim counts with low per-claim payment, indicating varied pricing/claim patterns across the drug mix rather than uniform high-dollar single items.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
108 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 20,600 | $40 | $885.8K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 16,560 | $40 | $629.3K |
| J9299 | Injection, nivolumab, 1 mg | 25,690 | $20 | $616.7K |
| J9173 | Injection, durvalumab, 10 mg | 5,790 | $60 | $359.1K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 8,840 | $40 | $335.9K |
| J0897 | Injection, denosumab, 1 mg | 10,560 | $20 | $200.6K |
| J9022 | Injection, atezolizumab, 10 mg | 2,860 | $60 | $182.8K |
| J1930 | Injection, lanreotide, 1 mg | 3,720 | $40 | $160K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 77,250 | $1 | $77.3K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 760 | $100 | $75.6K |
Showing 1–10 of 108
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 108 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
108 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 9 | 60 | 9,900 | $40 | $505.5K |
| J9144 | 5 | 20 | 10,440 | $40 | $499.4K |
| J9299 | 3 | 10 | 14,670 | $20 | $438.2K |
| J9173 | 1 | 10 | 5,380 | $60 | $334.5K |
| J9022 | 2 | 10 | 4,700 | $60 | $300.9K |
| J1930 | 3 | 10 | 3,840 | $40 | $241.5K |
| J1561 | 9 | 40 | 3,100 | $40 | $234.9K |
| J9264 | 2 | 10 | 9,610 | $10 | $90.8K |
| J0897 | 48 | 490 | 2,820 | $20 | $84.4K |
| Q5119 | 5 | 10 | 2,100 | $20 | $51.1K |
Showing 1–10 of 108
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 40 | $10 | $520 |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 10 | $20 | $180 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 18,474 | 19,110 | 360 | $70 | $321K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 13,033 | 16,550 | 220 | $90 | $186.8K |
Other providers in the same ZIP code as Tarek Sousou, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Syracuse Endoscopy Associates, LLC | NY | Endoscopy Clinic/Center | $560.3K | $1.1M |
| K&a Radiologic Technology Services Inc | NY | Portable X-ray and/or Other Portable Diagnostic Imaging Supplier | $638.2K | $89.1K |
| Upstate Orthopedics Ambulatory Surgery Center LLC | NY | Ambulatory Surgical Clinic/Center | $402.5K | $83.6K |
| Benny Wong | NY | Hematology & Oncology Physician | $403.7K | $7.3K |
| Vinod Varki | NY | Hematology & Oncology Physician | $388.7K | $0 |
| Aref Agheli | NY | Hematology & Oncology Physician | $364.3K | $1.8K |
| Jeffrey Cizenski | NY | Dermatology Physician | $290.7K | $0 |
| Robert Sherman | NY | Orthopaedic Surgery Physician | $258.5K | $5K |
| Traian Anghel | NY | Clinical Cardiac Electrophysiology Physician | $256K | $190 |
| Hassan Shukri-mahmod | NY | Neurology Physician | $215.9K | $12.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.